417722-93-1

Basic information

• Product Name: 4-(4-aMino-3-chlorophenoxy)-7-Methoxyquinoline-6-carboxaMide
• Synonyms: 4-(4-aMino-3-chlorophenoxy)-7-Methoxyquinoline-6-carboxaMide;Lenvatinib Impurity c;4-(4-amino-3-chlorophenoxy)-7-methoxy-6-Quinolinecarboxamide;4-(3-chloro-4-ureidophenoxy)-7-methoxyquinoline-6-carboxylic acid;Lenvatinib impurity;lenvaim-E;Lenvatinib Intermediates 1
• CAS NO: 417722-93-1
• Molecular Formula: C₁₇H₁₄ClN₃O₃
• Molecular Weight: 343.76436
• EINECS: -0
• Mol File: 417722-93-1.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 577.2±50.0 °C(Predicted)
• Appearance: /
• Density: 1.407±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 15.46±0.30(Predicted)
• CAS DataBase Reference: 4-(4-aMino-3-chlorophenoxy)-7-Methoxyquinoline-6-carboxaMide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-aMino-3-chlorophenoxy)-7-Methoxyquinoline-6-carboxaMide(417722-93-1)
• EPA Substance Registry System: 4-(4-aMino-3-chlorophenoxy)-7-Methoxyquinoline-6-carboxaMide(417722-93-1)

Safety Data

• Hazardous Substances Data: 417722-93-1(Hazardous Substances Data)

Usage

Uses

4-(4-Amino-3-chlorophenoxy)-7-methoxy-6-quinolinecarboxamide is an impurity of Lenvatinib (L329400), CAS# 417716-92-8.4-(4-Amino-3-chlorophenoxy)-7-methoxy-6-quinolinecarboxamide is also used in pharmaceutical studies with an analytical role as a reference standard in an HPLC method for analyzing Lenvatinib or its salt, allowing a strong specificity, accuracy, precision, and high sensitivity.

Upstream product

• 491-11-2 3-chloro-4-nitrophenol 
• 417721-36-9 4‐chloro‐7‐methoxyquinoline‐6‐carboxamide 
• 17609-80-2 4-amino-3-chlorophenol 
• 205448-66-4 methyl 4-chloro-7-methoxyquinoline-6-carboxylate 
• 52671-64-4 4-Amino-3-chlorophenol hydrochloride 
• 796848-79-8 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropyl urea 
• 417716-92-8 lenvatinib 
• 417724-81-3 7-methoxy-4-oxo-1,4-dihydroquinoline-6-carboxamide 
• 417721-35-8 7-methoxy-4-chloro-quinoline-6-carbonyl chloride 
• 417721-34-7 7-Methoxy-4-oxo-1,4-dihydroquinoline-6-carboxylic acid 
• 205448-65-3 7-methoxy-4-oxo-1,4-dihydroquinoline-6-carboxylic acid methyl ester 
• 205448-64-2 methyl 4-(((2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)methyl)-amino)-2-methoxybenzoate 
• 27492-84-8 Methyl 4-amino-2-methoxybenzoate 

Downstream Products

• 857890-39-2 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6-quinoline-carboxamide methanesulfonate 
• 417722-95-3 {4-[(6-carbamoyl-7-methoxy-4-quinolyl)oxy]-2-chlorophenyl}amino-carboxylic acid phenyl ester 
• 417716-92-8 lenvatinib 
• 417716-91-7 4-(3-Chloro-4-((2-thiazolylamino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide 
• 417716-90-6 4-(3-Chloro-4-((4-fluoroanilino)carbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide 

Relevant articles and documents

Novel method for the synthesis of lenvatinib using 4-nitrophenyl cyclopropylcarbamate and their pharmaceutical salts

4-Nitrophenyl cyclopropylcarbamate was deployed as a novel synthon for the synthesis of anticancer drug lenvatinib. 4-Nitrophenyl cyclopropylcarbamate was prepared by the reaction of 4-nitrophenyl chloroformate and cyclopropyl amine in acetonitrile at room temperature. Furthermore, lenvatinib was synthesized by reacting 4-(4-amino-3-chlorophenoxy)-7-methoxyquinoline-6-carboxamide with 4-nitrophenyl cyclopropylcarbamate in good yields. Apart from the synthesis of lenvatinib, citrate, phosphate, malate and oxalate salts of?lenvatinib were also reported in good yields.

Preparation method of lenvatinib intermediate

The invention discloses a preparation method of a lenvatinib intermediate. The preparation method comprises the following steps: carrying out a nucleophilic substitution reaction among a compound shown as a formula I, a compound shown as a formula II and

Preparation method of high-purity lenvatinib mesylate crystal form C

The invention belongs to the technical field of pharmaceutical chemicals and especially relates to a preparation method of a lenvatinib mesylate crystal form C. According to the method, the conditions of high temperature, acid serving as a solvent and the